youtube_live
Q3 2026 earnings • in 5 days
See detailschevron_right
WST:NYSE
West Pharmaceutical Services Inc
$392.15
arrow_downward
-0.48%(-1.88) 1D
$391.09
arrow_downward
-0.27% (-1.06)bedtimeAfter hours
Closed: Oct 23, 4:00:41 PM GMT-4 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for WST...
Open
$391.60
High
$394.18
Low
$389.72
Mkt. cap
27.60B
Avg. vol.
584.16K
Volume
718.05K
Dividend
0.27%
Quarterly dividend
$0.26
Ex-dividend date
Jul 29, 2026
P/E ratio
50.13
52-wk high
$397.16
52-wk low
$223.83
EPS
$7.82
Beta
1.13
Shares outstanding
70.38M
No. of employees
11K
Open
$391.60
High
$394.18
Low
$389.72
Mkt. cap
27.60B
Avg. vol.
584.16K
Volume
718.05K
Dividend
0.27%
Quarterly dividend
$0.26
Ex-dividend date
Jul 29, 2026
P/E ratio
50.13
52-wk high
$397.16
52-wk low
$223.83
EPS
$7.82
Beta
1.13
Shares outstanding
70.38M
No. of employees
11K
News stories
From web sources and news partners
MarketWatch
·
3 days ago
West Pharmaceutical Services Inc. stock outperforms competitors on strong trading day
Zacks Investment Research
·
3 days ago
Reasons to Add West Pharmaceutical Stock to Your Portfolio Now
Profile
West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. Founded in 1923 by Herman O. West and J.R. Wike of Philadelphia, the company is headquartered in Exton, Pennsylvania. In its early years of development, West produced rubber components for packaging injectable drugs, providing a sterile environment for the producers of penicillin and insulin. Wikipedia
About West Pharmaceutical Services Inc
CEOEric M. Green
Employees10.8K
Founded1923
HeadquartersWest Whiteland Township, Pennsylvania, United States
SectorHealth care
Websitewestpharma.com
Analyst ratings
Based on 6 analysts giving stock ratings to WST in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for WST in the last 3 months.
Highest
Current $392.15
$440.00 (+12.20%)
Average
$418.67 (+6.76%)
Lowest
$400.00 (+2.00%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Brendan Smith TD Cowen | Buy | Maintained | $420.00 | +7.1% | 10/13/2026 |
Luke Sergott Barclays | Buy | Maintained | $440.00 | +12.2% | 10/07/2026 |
Kallum Titchmarsh Morgan Stanley | Buy | Upgraded | $400.00 | +2% | 09/22/2026 |
Unknown Analyst UBS | Buy | Maintained | $415.00 | +5.8% | 09/09/2026 |
Doug Schenkel UBS | Buy | Maintained | $415.00 | +5.8% | 09/09/2026 |
Joanne Wuensch Citi | Buy | Maintained | $412.00 | +5.1% | 08/03/2026 |
Daniel Markowitz CFA Evercore ISI | Buy | Maintained | $425.00 | +8.4% | 07/27/2026 |
Michael Ryskin Bank of America Securities | Buy | Reiterated | $410.00 | +4.6% | 07/24/2026 |
Matt Larew William Blair | Buy | Maintained | - | - | 07/23/2026 |
Curtis Moiles Exane BNP Paribas | Buy | Initiated | $447.00 | +14% | 07/13/2026 |
Paul Knight KeyBanc | Buy | Maintained | $390.00 | -0.5% | 07/02/2026 |
Michael Polark Wolfe Research | Buy | Reiterated | $375.00 | -4.4% | 06/01/2026 |
Patrick B Donnelly Citi | Buy | Maintained | $400.00 | +2% | 04/24/2026 |
Vijay Kumar Evercore ISI | Buy | Maintained | - | - | 04/23/2026 |
Dan Leonard UBS | Buy | Maintained | $340.00 | -13.3% | 02/13/2026 |
Justin Bowers Deutsche Bank | Buy | Maintained | $315.00 | -19.7% | 02/13/2026 |
David Windley Jefferies | Buy | Maintained | $295.00 | -24.8% | 02/10/2026 |
Nico Chen DBS | Buy | Maintained | $320.00 | -18.4% | 01/28/2026 |
Next call in 5 days
Thu, Oct 29, 2:00 PM
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
- / $2.20
Revenue / Est. (USD)
- / 826.55M
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 804.60M | 805.00M | 844.90M | 872.30M |
Cost of goods sold | 510.30M | 501.10M | 548.50M | 543.10M |
Cost of revenue | 510.30M | 501.10M | 548.50M | 543.10M |
Research and development expenses | 17.10M | 21.80M | 15.80M | 19.70M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 101.10M | 107.50M | 99.50M | 112.00M |
Operating expense | 118.50M | 129.70M | 113.10M | 133.20M |
Total operating expenses | 628.80M | 630.80M | 661.60M | 676.30M |
Operating income | 175.80M | 174.20M | 183.30M | 196.00M |
Other non operating income | -200.00K | 600.00K | -200.00K | -200.00K |
EBT including unusual items | 174.00M | 165.40M | 183.50M | 186.20M |
EBT excluding unusual items | 179.50M | 181.20M | 188.60M | 201.20M |
Income tax expense | 34.00M | 33.30M | 44.70M | 32.20M |
Effective tax rate | 19.54% | 20.13% | 24.36% | 17.29% |
Other operating expenses | 300.00K | 400.00K | -2.20M | 1.50M |
Net income | 140.00M | 132.10M | 138.80M | 154.00M |
Net profit margin | 17.40% | 16.41% | 16.43% | 17.65% |
Earnings per share | 1.96 | 2.04 | 2.13 | 2.37 |
Interest and investment income | 4.70M | 5.30M | 5.10M | 3.80M |
Interest expense | -200.00K | - | -1.90M | -2.60M |
Net interest expenses | 4.50M | 5.30M | 3.20M | 1.20M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 218.80M | 221.20M | 228.50M | 242.20M |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events